ENDRA Life Sciences Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option

About this update from Endra Life Sciences Inc.

[{"type":"text","content":"ANN ARBOR, MI / ACCESSWIRE / December 18, 2020 / ENDRA Life Sciences Inc. (\"ENDRA\") (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today reported the closing of its previously announced underwritten public offering of 7,143,000 shares of common stock at an offering price of $0.70 per share. In connection with the offering, the underwriter exercised its over-allotment option to purchase an additional 714,286 shares of common stock at the public offering price, less the underwriting discount, in full. As a result, the total offering size was 7,857,286 shares, and the gross proceeds from the offering were $5,500,100, before deducting underwriting discounts and estimated offering expenses. All of the shares of common stock were offered by ENDRA.ThinkEquity, a division of Fordham Financial Management, Inc., acted as the sole underwriter for the offering.A shelf registration statement on Form S-3 (File No. 333-229090) relating to the shares of common stock issued in the proposed offering was filed with the Securities and Exchange Commission (the \"SEC\") and is effective. The final prospectus supplement relating to the offering was filed with the SEC on December 17, 2020. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, or by email at [email protected]. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the SEC's website at http://www.sec.gov.This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About ENDRA Life Sciences Inc.ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with the over one million ultrasound systems in use globally today. TAEUS is initially focused...

More updates from Endra Life Sciences Inc.